3 / 5
Journal of Clinical Immunology and Allergy
ISSN: 2471-304X
Page 23
16
th
EuroSciCon Conference on Immunology
March 11-12, 2019 | Amsterdam, Netherlands
Immunology 2019
O
peration BIM (balancing immunity) Research Project was established
with the goal of achieving a newdimension of health care utilizing refined
extracts from mangosteen, sesame, soy, guava and centella to boost the
function of white blood cells. One of the operation BIM formulations, LIV®
was found to stimulate body immunity by increasing Th17 conspicuously
and Th1 significantly. Clinical studies in HIV infected volunteers confirmed
that the formulation conspicuously boosted the CD4 count, reduced the side
effects from antiviral drugs and markedly improved the life quality of HIV
/AIDS infected patients. The formulation lowered the risk of stage 3 AIDS
patients from opportunistic infections by boosting their CD4 number to over
200 cells/mm
3
in 1-2 months. Final stage AIDS patients with CD4 less than
10 cells/mm
3
were able to raise their CD4 counts to an average of 500 cells/
mm
3
in 6 months. A number of patients with opportunistic infections were
able to remedy their symptoms within one year and have been living normally
with the viral load of less than 20 copies/mm
3
. In summary, LIV® boosts
CD4 count rapidly and can save lives of HIV/AIDS infected patients. A similar
formulation, ThPlus®, was used to improve the life quality of cancer patients.
Over the past 10 years, numerous cancer patients have recovered from their
symptoms and lived normally. In conclusion, the action of the formulation
is mediated by increasing Th17 and Th1 which then enhance the activity of
cytotoxic T cells in eliminating HIV infected CD4 cells and cancer cells.
Novel phytoceutical formula for
immunotherapy of HIV/AIDS and cancer
Pichaet Wiriyachitra
Asian Phytoceuticals Public Company Limited,Thailand
Biography
Pichaet Wiriyachitra has completed his PhD from
University of Tasmania and Postdoctoral Studies
from University of Connecticut and University of
Pennsylvania. He served in the Prince of Songkla
University and Chiang Mai University for 26 years
and published 80 scientific papers in reputed
journals both in Thai and English. He is the CEO
of Asian Phytoceuticals Public Company Limited
and the Principal Investigator of Operation BIM
Research Team consisting of Assoc Prof Dr Ampai
Panthong, Prof Dr Souwalak Phongpaichit, Assoc
Prof Dr Wilawan Mahabussarakam and Assoc Prof
Dr Siriwan Ong-chai.
pwapco@gmail.comPichaet Wiriyachitra, J Clin Immunol Allergy 2019, Volume:5
DOI: 10.21767/2471-304X-C1-007